Sandoz Launches First US Pirfenidone At-Risk After Court Triumphs

Esbriet Generic Launch Brings Competition To Narrow IPF Market

 
• By Dean Rudge

Sandoz has introduced the first generic version of Roche’s landmark treatment for idiopathic pulmonary fibrosis, Esbriet (pirfenidone), after downing the originator’s attempts to stymie its launch.

Court_Of_Appeals_USA
The Federal Circuit told Genentech an injunction wasn't warranted • Source: Shutterstock

More from Products

More from Generics Bulletin